Abstract CT101: A model-based exposure-response (E-R) assessment of a nivolumab (NIVO) 4-weekly (Q4W) dosing schedule across multiple tumor types-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Abstract CT101: A model-based exposure-response (E-R) assessment of a nivolumab (NIVO) 4-weekly (Q4W) dosing schedule across multiple tumor types

Published:2017-07-01 Issue: Volume: Page:
ISSN:
Container-title:Clinical Trials
language:
Short-container-title:

Author:

Zhao Xiaochen,Ivaturi Vijay,Gopalakrishnan Mathangi,Shen Jun,Feng Yan,Statkevich Paul,Richards Eric,Rashford Michelle,Goodman Vicki,Gobburu Joga,Bello Akintunde,Roy Amit,Agrawal Shruti

Publisher

American Association for Cancer Research

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and Safety of Salvage-line Nivolumab Monotherapy for Advanced Esophageal Squamous Cell Carcinoma: Comparison of 240 mg Versus 480 mg Doses;Journal of Gastrointestinal Cancer;2024-07-15

2. Lung Cancer;Fundamentals of Cancer Detection, Treatment, and Prevention;2022-05-13

3. An open label, safety study of Asian patients with advanced non-small-cell lung cancer receiving second-line nivolumab monotherapy (CheckMate 870);Therapeutic Advances in Medical Oncology;2022-01

4. Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors;Journal for ImmunoTherapy of Cancer;2021-06

5. Strategies to overcome relapse of immunotherapy-related hepatitis: dose reduction is not the key;Acta Clinica Belgica;2021-03-23

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP